Table 8 Demographic and clinical characteristics for the different genotypes of rs55646866 in UC patients

Gender

 Male (n = 369)

 Female (n = 321)

302 (53.3%)

265 (46.7%)

63 (56.8%)

48 (43.2%)

4 (33.3%)

8 (66.7%)

0.302

Age at diagnosis [years]

 Median, q25–q75,

 Min–max

28.0, 19.9–38.7,

2.9–79.6

30.7, 22.1–38.8,

3.9–69.4

18.3, 8.5–22.1,

3.4–49.2

0.004

Disease duration [years]

 Median, q25–q75,

 Min–max

11.1, 6.7–18.1,

0.2–49.5

13.2, 7.8–20.0,

0.5–38.3

10.2, 7.0–14.2,

4.6–40.1

0.192

Complications*

 No (n = 286)

 Yes (n = 404)

244 (43.0%)

323 (57.0%)

39 (35.1%)

72 (64.9%)

3 (25.0%)

9 (75.0%)

0.160

MTWAI—maximal value throughout follow-up

 Median, q25–q75,

 Min–max

5, 2–9,

0–19

5, 2–9,

0–17

1.5, 0–2.5,

0–14

0.009

Reported flare*

 No (n = 284)

 Yes (n = 406)

230 (40.6%)

337 (59.4%)

49 (44.1%)

62 (55.9%)

5 (41.7%)

7 (58.3%)

0.777

Flare possibly or highly related to (focus on yes):

 NSAIDs

 Antibiotics

 GI tract infection

 Other infection

 Treatment decr./disc

 Other medication

20 (5.9%)

6 (1.8%)

57 (16.9%)

32 (9.5%)

86 (25.5%)

10 (3.0%)

3 (4.8%)

2 (3.2%)

15 (24.2%)

5 (8.1%)

10 (16.1%)

4 (6.5%)

0 (0%)

0 (0%)

2 (28.6%)

2 (28.6%)

2 (28.6%)

0 (0%)

1.000

0.444

0.249

0.223

0.232

0.413

Flare management (focus on the yes):

 Hospitalization

 Ambulatory

 Surgery

 Drug therapy

42 (12.5%)

99 (29.4%)

17 (5.0%)

302 (89.6%)

4 (6.5%)

5 (8.1%)

2 (3.2%)

59 (95.2%)

0 (0%)

0 (0%)

0 (0%)

7 (100%)

0.375

 < 0.001

0.822

0.376

Focus on the hospitalizations:

 Total days of hosp.

 Median, q25–q75,

 Min–max

4, 0–14,

0–90

0, 0–6,

0–12

–

0.225